1 Introduction to Research & Analysis Reports 1.1 Chronic Myelogenous Leukemia Treatment Market Definition 1.2 Market Segments 1.2.1 Segment by Type 1.2.2 Segment by Application 1.3 United States Chronic Myelogenous Leukemia Treatment Market Overview 1.4 Methodology & Sources of Information 1.4.1 Research Methodology 1.4.2 Research Process 1.4.3 Base Year 2 United States Chronic Myelogenous Leukemia Treatment Overall Market Size 2.1 United States Chronic Myelogenous Leukemia Treatment Market Size: 2021 VS 2027 2.2 United States Chronic Myelogenous Leukemia Treatment Revenue, Prospects & Forecasts: 2016-2027 2.3 Key Market Trends, Opportunity, Drivers and Restraints 2.3.1 Market Opportunities & Trends 2.3.2 Market Drivers 2.3.3 Market Restraints 3 Company Landscape 3.1 Top Chronic Myelogenous Leukemia Treatment Players in United States Market 3.2 Top United States Chronic Myelogenous Leukemia Treatment Companies Ranked by Revenue 3.3 United States Chronic Myelogenous Leukemia Treatment Revenue by Companies 3.4 Top 3 and Top 5 Chronic Myelogenous Leukemia Treatment Companies in United States Market, by Revenue in 2020 3.5 Companies Chronic Myelogenous Leukemia Treatment Product Type 3.6 Tier 1, Tier 2 and Tier 3 Chronic Myelogenous Leukemia Treatment Players in United States Market 3.6.1 List of Tier 1 Chronic Myelogenous Leukemia Treatment Companies in United States 3.6.2 List of Tier 2 and Tier 3 Chronic Myelogenous Leukemia Treatment Companies in United States 4 Sights by Type 4.1 Overview 4.1.1 By Type - United States Chronic Myelogenous Leukemia Treatment Market Size Markets, 2021 & 2027 4.1.2 Disease Specific Treatment 4.1.3 Symptomatic Treatment 4.2 By Type - United States Chronic Myelogenous Leukemia Treatment Revenue & Forecasts 4.2.1 By Type - United States Chronic Myelogenous Leukemia Treatment Revenue, 2016-2021 4.2.2 By Type - United States Chronic Myelogenous Leukemia Treatment Revenue, 2022-2027 4.2.3 By Type - United States Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2016-2027 5 Sights by Application 5.1 Overview 5.1.1 By Application - United States Chronic Myelogenous Leukemia Treatment Market Size, 2021 & 2027 5.1.2 Hospital Pharmacies 5.1.3 Specialty Pharmacies 5.1.4 Retail Pharmacies 5.2 By Application - United States Chronic Myelogenous Leukemia Treatment Revenue & Forecasts 5.2.1 By Application - United States Chronic Myelogenous Leukemia Treatment Revenue, 2016-2021 5.2.2 By Application - United States Chronic Myelogenous Leukemia Treatment Revenue, 2022-2027 5.2.3 By Application - United States Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2016-2027 6 Chronic Myelogenous Leukemia Treatment Companies Profiles 6.1 Bristol-Myers Squibb 6.1.1 Bristol-Myers Squibb Company Details 6.1.2 Bristol-Myers Squibb Business Overview 6.1.3 Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Introduction 6.1.4 Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.1.5 Bristol-Myers Squibb Recent Developments 6.2 Novartis 6.2.1 Novartis Company Details 6.2.2 Novartis Business Overview 6.2.3 Novartis Chronic Myelogenous Leukemia Treatment Introduction 6.2.4 Novartis Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.2.5 Novartis Recent Developments 6.3 Pfizer 6.3.1 Pfizer Company Details 6.3.2 Pfizer Business Overview 6.3.3 Pfizer Chronic Myelogenous Leukemia Treatment Introduction 6.3.4 Pfizer Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.3.5 Pfizer Recent Developments 6.4 Teva Pharmaceuticals 6.4.1 Teva Pharmaceuticals Company Details 6.4.2 Teva Pharmaceuticals Business Overview 6.4.3 Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Introduction 6.4.4 Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.4.5 Teva Pharmaceuticals Recent Developments 6.5 Roche 6.5.1 Roche Company Details 6.5.2 Roche Business Overview 6.5.3 Roche Chronic Myelogenous Leukemia Treatment Introduction 6.5.4 Roche Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.5.5 Roche Recent Developments 6.6 Incyte 6.6.1 Incyte Company Details 6.6.2 Incyte Business Overview 6.6.3 Incyte Chronic Myelogenous Leukemia Treatment Introduction 6.6.4 Incyte Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.6.5 Incyte Recent Developments 6.7 Bio-Path Holdings 6.7.1 Bio-Path Holdings Company Details 6.7.2 Bio-Path Holdings Business Overview 6.7.3 Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Introduction 6.7.4 Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) 6.7.5 Bio-Path Holdings Recent Developments 7 Conclusion 8 Appendix 8.1 Note 8.2 Examples of Clients 8.3 Author Details 8.4 Disclaimer

List of Tables Table 1. Chronic Myelogenous Leukemia Treatment Market Opportunities & Trends in United States Market Table 2. Chronic Myelogenous Leukemia Treatment Market Drivers in United States Market Table 3. Chronic Myelogenous Leukemia Treatment Market Restraints in United States Market Table 4. Key Players of Chronic Myelogenous Leukemia Treatment in United States Market Table 5. Top Chronic Myelogenous Leukemia Treatment Players in United States Market, Ranking by Revenue (2019) Table 6. United States Chronic Myelogenous Leukemia Treatment Revenue by Companies, (US$, Mn), 2016-2021 Table 7. United States Chronic Myelogenous Leukemia Treatment Revenue Share by Companies, 2016-2021 Table 8. Companies Chronic Myelogenous Leukemia Treatment Product Type Table 9. List of Tier 1 Chronic Myelogenous Leukemia Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share Table 10. List of Tier 2 and Tier 3 Chronic Myelogenous Leukemia Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share Table 11. By Type – United States Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2021 & 2027 Table 12. By Type - United States Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), 2016-2021 Table 13. By Type - United States Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), 2022-2027 Table 14. By Application – United States Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2021 VS 2027 Table 15. By Application - United States Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), 2016-2021 Table 16. By Application - United States Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), 2022-2027 Table 17. Bristol-Myers Squibb Company Details Table 18. Bristol-Myers Squibb Business Overview Table 19. Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Product Table 20. Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 21. Bristol-Myers Squibb Recent Developments Table 22. Novartis Company Details Table 23. Novartis Business Overview Table 24. Novartis Chronic Myelogenous Leukemia Treatment Product Table 25. Novartis Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 26. Novartis Recent Developments Table 27. Pfizer Company Details Table 28. Pfizer Business Overview Table 29. Pfizer Chronic Myelogenous Leukemia Treatment Product Table 30. Pfizer Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 31. Pfizer Recent Developments Table 32. Teva Pharmaceuticals Company Details Table 33. Teva Pharmaceuticals Business Overview Table 34. Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Product Table 35. Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 36. Teva Pharmaceuticals Recent Developments Table 37. Roche Company Details Table 38. Roche Business Overview Table 39. Roche Chronic Myelogenous Leukemia Treatment Product Table 40. Roche Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 41. Roche Recent Developments Table 42. Incyte Company Details Table 43. Incyte Business Overview Table 44. Incyte Chronic Myelogenous Leukemia Treatment Product Table 45. Incyte Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 46. Incyte Recent Developments Table 47. Bio-Path Holdings Company Details Table 48. Bio-Path Holdings Business Overview Table 49. Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Product Table 50. Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue in United States Market (2016-2021) & (US$ Million) Table 51. Bio-Path Holdings Recent Developments List of Figures Figure 1. Chronic Myelogenous Leukemia Treatment Segment by Type Figure 2. Chronic Myelogenous Leukemia Treatment Segment by Application Figure 3. United States Chronic Myelogenous Leukemia Treatment Market Overview: 2020 Figure 4. United States Chronic Myelogenous Leukemia Treatment Market Size: 2021 VS 2027 (US$, Mn) Figure 5. United States Chronic Myelogenous Leukemia Treatment Revenue, 2016-2027 (US$, Mn) Figure 6. The Top 3 and 5 Players Market Share by Chronic Myelogenous Leukemia Treatment Revenue in 2020 Figure 7. By Type - United States Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2016-2027 Figure 8. By Application - United States Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2016-2027 Figure 9. Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 10. Novartis Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 11. Pfizer Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 12. Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 13. Roche Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 14. Incyte Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 15. Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)

Bristol-Myers Squibb Novartis Pfizer Teva Pharmaceuticals Roche Incyte Bio-Path Holdings